Developing a reliable and validated screening assay for hepatitis B associated livercancers.
- Conditions
- Health Condition 1: C220- Liver cell carcinoma
- Registration Number
- CTRI/2020/09/027891
- Lead Sponsor
- Manipal Academy of Higher Education
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Chronic hepatitis B positive (HBsAg/Anti HBc IgG) with no radiological evidence of liver fibrosis.
Chronic hepatitis B positive liver cirrhosis cases diagnosed with upper GI endoscopic data of esophageal/gastric varices, portal hypertension or radiological features.
Anti-HBc IgG positive Hepatocellular carcinoma cases will be identified by ultrasonography or with or without histological evidence.
Anti-HBc IgG negative hepatocellular carcinoma cases diagnosed by ultrasonography with or without histological evidence.
Normal healthy controls.
Patients with other liver diseases, pregnant women, individuals below 18 years of age, co-infection with HIV, Hepatitis C virus (HCV), serious concurrent medical illnesses like malignancy and uncontrolled diabetes mellitus will be excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Our study will become a platform for developing highly specific multiple microRNA based screening assay for other cancers like HPV associated oropharyngeal and anal cancers for which there does not exist a recommended screening tool.Timepoint: 2 years
- Secondary Outcome Measures
Name Time Method Tumour specific miRNA targets will facilitate drug development leading to precision medicine with minimal side effectsTimepoint: 2 years